ulimorelin and Inflammatory-Bowel-Diseases

The therapeutic potential of ghrelin and synthetic ghrelin receptor (GRLN-R) agonists for the treatment of gastrointestinal (GI) motility disorders is based on their ability to stimulate coordinated patterns of propulsive GI motility. This review focuses on the latest findings that support the therapeutic potential of GRLN-R agonists for the treatment of GI motility disorders. The review highlights the preclinical and clinical prokinetic effects of ghrelin and a series of novel ghrelin mimetics to exert prokinetic effects on the GI tract. We build upon a series of excellent reviews to critically discuss the evidence that supports the potential of GRLN-R agonists to normalize GI motility in patients with GI hypomotility disorders such as gastroparesis, post-operative ileus (POI), idiopathic chronic constipation and functional bowel disorders.

Topics: Animals; Chronic Disease; Constipation; Gastrointestinal Agents; Gastrointestinal Motility; Gastroparesis; Ghrelin; Guinea Pigs; Humans; Ileus; Inflammatory Bowel Diseases; Macrocyclic Compounds; Mice; Postoperative Complications; Receptors, Ghrelin